Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Effect of rosuvastatin on sortilin and fetuin-A in type 2 diabetic patients: a randomized controlled trial
ConclusionRosuvastatin co-treatment in T2DM patients improves glycemic control and aids in decreasing the atherogenic biomarkers sortilin and fetuin-A levels, so it can be considered tolerable and efficient in improving lipid profile and atherogenic index.Trial registrationClinicalTrials.gov identifier (NCT number): NCT03907423, (The registration date: April 9, 2019).https://clinicaltrials.gov/ct2/show/NCT03907423. (Source: International Journal of Diabetes in Developing Countries)
Source: International Journal of Diabetes in Developing Countries - March 2, 2024 Category: Endocrinology Source Type: research
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
CONCLUSION: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03864042, registered 6 March 2019.PMID:38424308 | DOI:10.1007/s40262-024-01352-9 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Joseph Piscitelli Micaela B Reddy Lance Wollenberg Laurence Del Frari Jason Gong Linda Wood Yizhong Zhang Kyle Matschke Jason H Williams Source Type: research
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
CONCLUSION: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03864042, registered 6 March 2019.PMID:38424308 | DOI:10.1007/s40262-024-01352-9 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Joseph Piscitelli Micaela B Reddy Lance Wollenberg Laurence Del Frari Jason Gong Linda Wood Yizhong Zhang Kyle Matschke Jason H Williams Source Type: research
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
CONCLUSION: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03864042, registered 6 March 2019.PMID:38424308 | DOI:10.1007/s40262-024-01352-9 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Joseph Piscitelli Micaela B Reddy Lance Wollenberg Laurence Del Frari Jason Gong Linda Wood Yizhong Zhang Kyle Matschke Jason H Williams Source Type: research
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
ConclusionThe results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.Clinical Trial RegistrationClinicalTrials.gov NCT03864042, registered 6 March 2019. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - February 29, 2024 Category: Drugs & Pharmacology Source Type: research
Rosuvastatin effect on atherosclerotic plaque metabolism: A subclinical atherosclerosis imaging study with 18F –NaF PET-CT
Atherosclerotic plaque fluorine-18 sodium fluoride (18F –NaF) uptake on positron emission tomography with computed tomography (PET-CT) identifies active microcalcification and has been shown to correlate with clinical instability in patients with cardiovascular (CV) disease. Statin therapy promotes coronary macrocalcification over time. Our aim was to investigate rosuvastatin effect on atheroma 18F–NaF uptake. (Source: Atherosclerosis)
Source: Atherosclerosis - February 28, 2024 Category: Cardiology Authors: Manuel Oliveira-Santos, Jo ão Borges-Rosa, Rodolfo Silva, Luís Paixão, Cláudio Espírito Santo, Antero Abrunhosa, Miguel Castelo-Branco, Lino Gonçalves, Maria João Ferreira, Piotr J. Slomka Source Type: research
From trials on rosuvastatin production waste valorization to development of new catalytic methods for Z → E isomerization of alkenes
New J. Chem., 2024, Advance Article DOI: 10.1039/D3NJ05865D, PaperAgata Tyszka-Gumkowska, B łażej Peta, Kamil Kosik, Emil Szepiński, Anna Kajetanowicz, Karol Grela A convenient method forZ→E geometry isomerization of aryl –aryl (stilbenes), alkyl–aryl, and alkyl–alkyl alkenes was developed. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - New J. Chem. latest articles)
Source: RSC - New J. Chem. latest articles - February 26, 2024 Category: Chemistry Authors: Agata Tyszka-Gumkowska Source Type: research
Viruses, Vol. 16, Pages 306: Rosuvastatin as a Supplemental Treatment for the Clinical Symptoms of Nephropathia Epidemica: A Pilot Clinical Study
This study aimed to assess the impact of rosuvastatin on the clinical and laboratory results of NE. A total of 61 NE patients and 30 controls were included in this study; 22 NE patients and 7 controls received a daily dose of rosuvastatin (10 mg) for ten consecutive days. Serum samples were collected on days 1, 5, and 10 after admission to the hospital. These samples were analyzed to determine the levels of lipids, cytokines, and kidney toxicity markers. Our findings indicate that rosuvastatin reduced the duration of the second wave of fever and alleviated back pain and headache symptoms. Additionally, low-density lipoprot...
Source: Viruses - February 17, 2024 Category: Virology Authors: Venera Shakirova Maria Markelova Yuriy Davidyuk Robert J. Stott-Marshall Toshana L. Foster Svetlana Khaiboullina Albert Rizvanov Ekaterina Martynova Tags: Article Source Type: research
